<DOC>
	<DOCNO>NCT02113163</DOCNO>
	<brief_summary>The primary objective study contrast pharmacokinetic profile metformin EPA deliver separately co-administered product ( metformin hydrochloride Glucophage icosapent ethyl Vascepa ) together solid dose form ( metformin eicosapentaenoate TP-101 ) fast fed condition . A secondary objective evaluate safety tolerability single repeat single dose TP-101 .</brief_summary>
	<brief_title>PK Study Comparing Metformin Eicosapentaenoate Combined Dose Metformin Hydrochloride Ethyl Ester EPA</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Signed informed consent execute prior protocol screen assessment ; Men woman 18 65 year age , inclusive ( Women may surgically sterile via tubal ligation , bilateral oophorectomy hysterectomy postmenopausal &gt; 1 year . Women childbearing potential must agree practice adequate contraception one month first dose study medication Day 16 study . Adequate contraception may include , limited , abstinence , monogamous relationship vasectomize partner , barrier method condom diaphragms spermicide foam , intrauterine device , license hormonal method . ) ; No history chronic disease , except subject wellcontrolled hypertension wellcontrolled hyperlipidemia ; BMI â‰¤30kg/m2 ; No significant medical history include diabetes hypertension complicate hyperlipidemia ( metabolic syndrome ) ; Negative urine drug alcohol test Screening ; , No metformin omega3 product within 2 month . Abnormal finding physical examination , EKG , vital sign , clinical laboratory testing , judgment investigator ; Allergies fish shellfish ; Impaired renal function ( calculate eGFR &lt; 60 mL/min ) ; Abnormal laboratory value T3 , T4 TSH Screening Visit ; Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 2x upper limit normal ( ULN ) serum bilirubin &gt; 1.5 mg/dL ; Requirement prescription medication within 14 day Screening Visit , exception prescription medication prevention pregnancy , anti hypertensive hypertension , statins hyperlipidemia . Doses one two antihypertensive and/or statin must stable &gt; 1 month ; Normal dose overthecounter medication , include vitamin allow within 3 day Visit 2 ( first day dose ) ; Current history abuse alcohol illicit drug within precede year Screening Visit ; Participation dietary modification intensive weight loss program ; Participation another clinical trial investigational product within 3 month prior Screening Visit ; Smokers ( use tobacco past 3 month ) ; , Donation loss 400 mL blood last 8 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>T2DM</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>severe hypertriglyceridemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>triglyceride</keyword>
	<keyword>lipid</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>EPA</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>Metformin</keyword>
	<keyword>Glucophage</keyword>
	<keyword>Lovaza</keyword>
	<keyword>Vascepa</keyword>
	<keyword>Epanova</keyword>
	<keyword>Astra Zeneca</keyword>
	<keyword>Amarin</keyword>
	<keyword>GSK</keyword>
</DOC>